We analyzed the disease-specific outcomes of adult ALL treated with cord blood transplantation (CBT) after myeloablative conditioning. Between October 2000 and November 2007, 27 adult patients with ALL were treated with unrelated CBT. All patients received four fractionated 12 Gy TBI and chemotherapy as myeloablative conditioning. The median age was 36 years, the median weight was 57 kg and the median number of nucleated cells was 2.47 Â 10 7 /kg. All patients received a single and HLA-mismatched cord blood unit. The cumulative incidence of neutrophil recovery at day 30 and platelet recovery at day 200 was 92.6 and 92.3%, respectively. With a median follow-up of 47 months, the probability of EFS at 5 years was 57.2%. The 5-year cumulative incidence of TRM and relapse was 3.7 and 27.4%, respectively. These results suggest that unrelated CBT after myeloablative conditioning could be safely and effectively used for adult patients with ALL.
Introduction
Recently, umbilical cord blood from unrelated donors has been used as an alternative stem cell source for adult patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, reports of disease-specific outcomes for adult patients with ALL after cord blood transplantation (CBT) are still limited. We have previously reported the results of a group of adult patients with ALL who received unrelated CBT. 7 Here, we updated the results of unrelated CBT after myeloablative conditioning for 27 adult patients with ALL. The main purpose of this retrospective single-center study was to confirm the safety and efficacy of unrelated CBT for adult ALL patients after a myeloablative conditioning regimen as well as to identify pre-transplant factors related to the transplant outcomes on long-term follow-up.
Patients and methods

Patients
This was a retrospective single-center analysis. Between October 2000 and November 2007, 27 adult patients with ALL were treated with unrelated CBT at The Institute of Medical Science, University of Tokyo. Patients qualified as being standard risk if they were in first or second CR. Patients in third CR, in relapse, or with refractory disease were classified as being high-risk. Patients were eligible for allogeneic transplantation in CR1 only if they had at least one of the following poor prognosis features: presence of t(9;22) or t(4;11); age above 35 years; elevated WBC count at diagnosis (430 000 for B-ALL and 4100 000 for T-ALL). Thirteen patients included in our previous study were also included and extended the follow-up. 7 Written informed consent for treatment was obtained from all patients.
Cord blood unit selection Antigens HLA-A and HLA-B were identified by serological typing. HLA-DRB1 alleles were determined by highresolution molecular typing using PCR sequence-specific primers (PCR-SSP). Matching at HLA-C, DQ and DP were not considered. Patients without a suitable closely HLA-matched family donor were eligible for CBT if a matched unrelated BM donor was unavailable as a first treatment option. If there was insufficient time for an unrelated BM donor search due to disease status, or the preliminary search indicated a low likelihood of obtaining a matched unrelated BM donor, we attempted to locate cord blood grafts. Preferred cord blood units matched three or more of six HLA loci and contained a minimal cell count of 1.5 Â 10 7 nucleated cells/kg before freezing. All cord blood units were obtained from cord blood banks in the Japan Cord Blood Bank Network.
Conditioning
Twelve patients received four fractionated 12 Gy TBI and CY, which was administered intravenously over 2 h at a dose of 60 mg/kg once daily on days À4 and À3 or days À3 and À2 (total dose 120 mg/kg). Eleven patients received four fractionated 12 Gy TBI, Ara-C, which was administered intravenously over 2 h at a dose of 3 g/m 2 every 12 h on days À5 and À4 (total dose 12 g/m 2 ) and CY on days À3 and À2 (total dose 120 mg/kg). Two patients, who had a cardiac damage as a result of extensive previous therapies, received four fractionated 12 Gy TBI, Ara-C 3 g/m 2 every 12 h on days -5 to -2 (total dose 24 g/m 2 ) and fludarabine, which was administered intravenously at a dose of 30 mg/ m 2 once daily on days -5 to -3. Two patients received four fractionated 12 Gy TBI, fludarabine 30 mg/m 2 once daily on days -6 to -4 and melphalan, which was administered intravenously at a dose of 70 mg/m 2 once daily on days À3 and À2 as conditioning. At 2 or 3 days after the completion of conditioning, patients received a CBT.
GVHD prophylaxis
All patients received standard CYA and MTX as GVHD prophylaxis. CYA was given intravenously every day starting on day À1 at a dose of 3 mg/kg/day. MTX (15 mg/m 2 intravenously) was given on day 1, and 10 mg/m 2 on days 3 and 6. Once oral intake could be tolerated, patients were administered oral CYA at a dose of 1:2, in two divided doses per day based on the last i.v. dose. In the absence of GVHD, CYA was tapered beginning between weeks 6 and 9 until it could be discontinued in the absence of chronic GVHD between 6 and 12 months after transplantation. CYA was reduced when serum creatinine levels increased above 1.5 times baseline or other serious agent-associated toxicities occurred. Physicians could freely modify the CYA dose for patients experiencing severe acute GVHD or risk of disease relapse. Corticosteroid-based treatment was considered when grade II or higher severe acute GVHD occurred (0.5-2 mg/kg).
Supportive care
All patients received G-CSF by i.v. infusion starting on day 1 until durable granulocyte recovery was achieved. The supportive care regimen, including prophylaxis, for infection was the same as previously reported. 8 End points and definitions Myeloid engraftment was defined as the first of 3 consecutive days, during which the absolute neutrophil count was at least 0.5 Â 10 9 /l. Platelet recovery time was achieved on the first of 3 days when the platelet count was higher than 5 Â 10 9 /l without transfusion support. The chimerism status after CBT was determined either by FISH with a Y chromosome probe for sex-mismatched CBT or by quantitative PCR analysis for microsatellite DNA markers. Primary engraftment failure was defined as the absence of donor-derived myeloid cells on the day of death, the day of relapse, the day of second allogeneic transplantation or the day 60 in patients surviving after CBT. Both acute and chronic GVHD were graded according to the previously published criteria. 10 ,11 TRM was defined as death from any cause except relapse. Relapse was defined by morphological evidence of disease in peripheral blood, BM or extramedullary sites. EFS was defined as the time from CBT to graft failure, relapse, death or last observation.
Statistical analysis
Cumulative incidences were estimated for hematopoietic recovery, GVHD, TRM and relapse to take competing risks into account. The probability of EFS was estimated from the time of CBT according to the Kaplan-Meier method. Variables considered in univariate analysis were as follows: body weight, age, recipient sex, degree of ABO matching, degree of HLA matching, cytogenetics at diagnosis (presence of t(9;22) or t(4;11), or negative), disease status at transplant (standard or high risk), total nucleated cell (TNC) dose and CD34 positive cell dose. As only two recipients were CMV seronegative before CBT, recipient CMV serostatus was not considered as a variable. Multivariate analysis was not performed due to the limited number of cases. P-values o0.05 were considered to be statistically significant. R version 2.4.1 was used for all analysis. End points were calculated at the last contact, the date of the last follow-up being 1 April 2008.
Results
Characteristics of patients and cord blood units
The characteristics of 27 patients and cord blood units are shown in Table 1 . Among the patients, the median age was 36 years (range, 18-55 years), the median weight was 57 kg (range, 39-76 kg), the median number of cryopreserved nucleated cells was 2.47 Â 10 
Hematopoietic recovery
Twenty-five patients had myeloid reconstitution, and the median time to more than 0.5 Â 10 9 /l ANC was 21 days (range, 17-30 days). Two patients experienced primary engraftment failure. Of the two patients, one died of hepatic veno-occlusive disease at day 18 without myeloid engraftment. The other patient received second CBT on day 40 after first transplantation. The cumulative incidence of neutrophil recovery at day 30 was 92.6% (95% confidence interval (CI), 81.1-100%). Male gender was identified as a significant factor affecting faster neutrophil recovery (P ¼ 0.01). A selfsustained platelet counts more than 50 Â 10 9 /l was achieved in 24 patients at a median time of 48 days (range, 32-204 days). The cumulative incidence of platelet recovery at day 200 was 92.3% (95% CI, 81.1-100%). Younger recipient age (o36 years) was significantly associated with faster platelet recovery (P ¼ 0.031).
II in 17 patients. There were no patients of grades III-IV acute GVHD. The cumulative incidence of grade II acute GVHD at day 100 after CBT was 63.6% (95% CI, 43.3-83.9%). No factor was associated with the incidence of grade II acute GVHD. Chronic GVHD occurred in 21 of 22 evaluable patients. Among 21 chronic GVHD patients, five patients were extensive-type. The cumulative incidence of overall and extensive-type chronic GVHD was 74.1 (95% CI, 56.8-91.4%) and 18.5% (95% CI, 3.5-33.5%), respectively. No factor was associated with the incidence of overall and extensive-type chronic GVHD.
Relapse
The cumulative incidence of relapse at 5 years was 27.4% (95% CI, 9.6-45.2%). A higher TNC dose at freezing was associated with an increased risk of relapse (P ¼ 0.022).
TRM and causes of death
The cumulative incidence of TRM at 5 years was 3.7% (95% CI, 0-11.0%). No factor was associated with TRM. Seven patients died. Of seven patients, five patients died of relapse, one died of hepatic veno-occlusive disease on day 18 and one died of secondary myelodysplastic syndrome of donor-origin on day 444 after first CBT.
EFS
Of 27 patients, 17 are alive and event-free after CBT. Median follow-up of EFS was 47 months (range, 4-90 months). The probability of EFS at 5 years was 57.2% (95% CI, 39.7-82.4%; Figure 1 ). Cytogenetics at diagnosis and disease status at transplant were not associated with EFS. A trend for better EFS was identified for male gender (P ¼ 0.09). A higher TNC dose at freezing was identified as an unfavorable factor affecting EFS (P ¼ 0.004).
Discussion
Several studies have suggested the promising results of unrelated CBT after myeloablative conditioning for adult patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, the factors associated with hematopoietic recovery were not fully described. Recently, Arcese et al.
12 reported the updated results of a large series of adult patients with different hematopoietic malignancies transplanted in 63 centers of the Eurocord group. One hundred and seventy-one adult patients received CBT after myeloablative conditioning. They analyzed outcomes and risk factors after CBT. The cumulative incidence of neutrophil 
Cytogenetics at diagnosis t(9;22), n 9 CR1, n 6 CR2, n 2 CR3, n 1 t(4;11) CR1, n 1 Others, n 3 Normal, n 14
Conditioning regimen TBI +CY, n 12 TBI+Ara-C +CY, n 11 TBI+Ara-C +Flu, n 2 TBI+Mel +Flu, n 2
GVHD prophylaxis CYA+MTX, n 27
No. of HLA-A, B, DRB1 mismatches 1, n 1 2, n 18 3, n 7 4, n 1 ABO compatibility Match, n 10 Mismatch, n 17
Abbreviations: Flu ¼ fludarabine; Mel ¼ melphalan. a Poor prognosis features: presence of t(9;22) or t(4;11); age above 35 years; elevated WBC count at diagnosis (430 000 for B-ALL and 4100 000 for T-ALL).
recovery at day 60 was 72% and the median time to neutrophil recovery was 28 days. In multivariate analysis, the number of nucleated cells at collection or freezing and the use of hematopoietic growth factors within 1 week after transplant were associated with faster neutrophil recovery. In our study, the cumulative incidence of neutrophil recovery at day 30 was 92.6% and the median time to neutrophil recovery was 21 days. Of 27 patients, only two patients experienced primary engraftment failure. Although TNC dose and CD34 positive cell dose were not associated with faster neutrophil recovery, male gender was identified as a significant factor affecting faster neutrophil recovery. One reason may be that two patients who experienced primary engraftment failure were female. All patients received G-CSF by i.v. infusion starting on day 1 until durable granulocyte recovery was achieved. Therefore, the use of hematopoietic growth factors may be associated with faster neutrophil recovery after CBT in adult setting. In our study, although there were no patients of grades III-IV acute GVHD, the cumulative incidence of grade II acute GVHD, overall and extensive-type chronic GVHD was 63.6, 74.1 and 18.5%, respectively. The incidence of acute and chronic GVHD was relatively higher than other reports of adult CBT; [1] [2] [3] [4] [5] [6] 12 however, the cumulative incidence of TRM at 5 years was very low (3.7%). Therefore, acute and chronic GVHD were not related to TRM in this study. As described before, 8 immunosuppressants for CBT recipients tended to be discontinued faster in our institution. This may be one of the reasons of the relatively higher incidence of GVHD. Also, we found no effect of HLA matching on acute GVHD as other reports of adult CBT. 1, 12 In the report of Rocha et al., 6 98 adult patients received CBT. Among the 98 patients, 53 were ALL and the 2-year probability of leukemia-free survival was 34%. As this report was registry-based retrospective studies comparing the results of unrelated CBT and unrelated BMT in adults, the details of outcomes of ALL were not described. Although we have previously reported the results of 13 adult patients with ALL who received CBT after myeloablative conditioning, 7 the follow-up duration after CBT was short and risk factors associated with transplant outcomes were not analyzed. Our recent report compared unrelated CBT and related donor grafts in adult patients, 9 including 20 patients with ALL who received CBT. However, the details of outcomes were not analyzed. At present, therefore, there have been no reports detailing the long-term follow-up results of disease-specific outcomes of adult ALL patients treated with CBT after myeloablative conditioning. In this analysis, unrelated CBT after myeloablative conditioning can cure approximately 60% adult patients with ALL. The low incidence of TRM and the GVL effect may be associated with encouraging outcomes. Also, Japanese patients might have some advantages in the setting of HLA-mismatched transplantation due to HLA or non-HLA immune genetics. A trend for better EFS was identified for male gender, and a higher TNC dose at freezing was identified as an unfavorable factor affecting relapse and EFS. However, many published reports showed that a higher TNC dose was a favorable factor affecting survival. One reason underlying these findings was that the median weight of female patients was low (48 kg in female, 60 kg in male) and the median number of TNC of female patients was high (2.99 Â 10 7 /kg in female, 2.30 Â 10 7 /kg in male). Arcese et al. 12 and others 13 as well as our study reported that female gender was associated with poorer disease-free survival. However, the reasons for the association of gender and TNC dose with EFS remain unclear due to the limited number of patients. A larger-sized study is needed. In summary, these results suggest that unrelated CBT after myeloablative conditioning could be safely and effectively used for adult ALL patients, and adult ALL patients without suitable related or unrelated BM donors should be considered as candidates for CBT. Striker 
